HIIFS
AVIR icon

Harel Insurance Investments & Financial Services’s Atea Pharmaceuticals AVIR Stock Holding History

Harel Insurance Investments & Financial Services’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-20,000
Closed -$701K – 748
2021
Q3 		$701K Buy
+20,000
New +$555K 0.02% 194

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
Voloridge Investment Management
Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return

Harel Insurance Investments & Financial Services's AVIR Position: Q4 2021 in Review

Harel Insurance Investments & Financial Services sold out of Atea Pharmaceuticals (AVIR) in Q4 2021, closing a stake of 20,000 shares — an estimated $701K sold.

Harel Insurance Investments & Financial Services first reported a position in AVIR in Q3 2021 and held it in 1 quarter. The position peaked at $701K in Q3 2021. 143 funds tracked by Wall St. Rank hold AVIR as of Q4 2021.

  • Harel Insurance Investments & Financial Services reported no remaining Atea Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Harel Insurance Investments & Financial Services sold 20,000 Atea Pharmaceuticals shares in Q4 2021, an estimated $701K.
  • Harel Insurance Investments & Financial Services first reported a position in Atea Pharmaceuticals in Q3 2021 and held it in 1 quarter.
  • Harel Insurance Investments & Financial Services's Atea Pharmaceuticals position peaked at $701K in Q3 2021.
  • 143 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q4 2021.

Based on Harel Insurance Investments & Financial Services's 13F filing for Q4 2021, filed 7 Feb 2022.